Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Centers for Medicare and Medicaid Services (CMS) has assigned a unique, permanent Healthcare Common Procedure Coding System (HCPCS) J-code for Eisai's Halaven (eribulin mesylate) Injection.
Subscribe to our email newsletter
Halaven is a non-taxane, microtubule dynamics inhibitor that is a synthetic analog of halichondrin B, a natural product that was isolated from the marine sponge Halichondria okadai.
Halaven inhibits the growth phase of microtubule dynamics, which can cause a cell to stop dividing and self-destruct.
The injection was approved in November 2010 to treat metastatic breast cancer that has spread in patients who have received at least two other types of anticancer medicines.
The new J-code, J9179, became effective on 1 January 2012.